Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)

NCT04799249 is registered in ClinicalTrials.gov with G1 Therapeutics, Inc. as lead sponsor.

NCT NCT04799249
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04799249 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)
Lead sponsor
G1 Therapeutics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
May 14, 2021
Completion date
May 24, 2024
Enrollment
194 (actual)
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, tnbc - triple-negative breast cancer